Abstract
Purpose: To evaluate the ocular toxidty of intravitreous transforming growth factor-beta 1 (TGF-β1).
Methods: Eyes of New Zealand white rabbits were injected intravitreally with TGF-β1 in doses of 20,10, 5, 1 or 0.5 µg. Electroretinography and clinical examination were performed before and after the injection. At either 10 or 30 days after injection, the eyes were enucleated and examined histologically. The endothelium of fresh corneas, which had received 20 µg TGF-β or nothing, were checked 5 days after injection.
Results: Corneal opacity was caused by doses ≥10 µg in 7 of 7 eyes; by doses of 5 µg in 3 of 4 eyes; and by doses of 1 µg in 1 of 4 eyes. Doses ≥ 5 µg also caused pannus formation in 15 of 16 eyes. Ten days after injection there was some decrease in B-wave amplitude on electroretinography. Thirty days after injection the electroretinographic responses had recovered, except in the eyes injected with 20 µg TGF-β1, which still showed a decrease in step 1. Histological examination of paraffin sections did not demonstrate significant change. Corneal thickness of the eyes receiving 20 µg TGF-β1 was twice that of the normal cornea and some corneal endothelial cells lost their hexagonal shape.
Conclusion: TGF-β1 injected intravitreally at doses ≥1 µg is toxic to the cornea. Retinal function is only slightly disturbed by 20 µg of TGF β1.
Similar content being viewed by others
Article PDF
References
Moses HL, Branum EL, Proper JA, Robinson RA . Transforming growth factor production by chemically transformed cells. Cancer Res 1981;41:2842–8.
Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB . New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 1981;78:5339–43.
Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B . Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 1987;105:1039–45.
Proper JA, Bjornson CL, Moses HL . Mouse embryos contain polypeptide growth factor(s) capable of inducing a reversible neoplastic phenotype in nontransformed cells in culture. J Cell Physiol 1982;110:169–74.
Jampel HD, Roche N, Stark WJ, Roberts AB . Transforming growth factor-β in human aqueous humor. Curr Eye Res 1990;9:963–9.
Cousins SW, McCabe MM, Danielpour D, Streilein JW . Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991;32:2201–11.
Pasquale LR, Dorman-Pease ME, Lutty GA, Jampel HD . Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 1993;34:23–30.
Peress NS, Perillo E . TGF-beta 2 and TGF-beta 3 immunoreactivity within the ciliary epithelium [published erratum appears in Invest Ophthalmol Vis Sci 1994;35:4A]. Invest Ophthalmol Vis Sci 1994;35:453–7.
Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS . Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 1993;34:477–87.
Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA . Transforming growth factor-β2 for the treatment of full-thickness macular holes: a prospective randomized study. Ophthalmology 1992;99:1162–73.
Stocker FW, King EH, Lucas DO, Georgiade NA . Clinical test for evaluating donor corneas. Arch Ophthalmol 1970;84:2–7.
Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–71.
Fiegel VD, Knighton DR, Nelson RD . Transforming growth factor-beta causes indirect angiogenesis by recruiting monocytes. FASEB J 1988;2:1601.
Liu J, Hales AM, Chamberlain CG, McAvoy JW . Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta. Invest Ophthalmol Vis Sci 1994;35:388–401.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liang, C., Peyman, G. & Federman, J. Ocular toxicity of intravitreous transforming growth factor-beta 1. Eye 10, 709–713 (1996). https://doi.org/10.1038/eye.1996.165
Issue Date:
DOI: https://doi.org/10.1038/eye.1996.165